Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9646327 | Schizophrenia Research | 2005 | 10 Pages |
Abstract
At present, more than 400 patients have been recruited and randomized in the following countries: Austria, Belgium, Bulgaria, Czech Republic, Germany, France, Israel, Italy, the Netherlands, Poland, Rumania, Spain, Sweden and Switzerland: The study should be finished by the end of 2006 and it is expected that results will yield relevant clinical information with regard to the effectiveness of the second generation antipsychotics. This effort represents the first independently designed trans-European schizophrenia treatment trial.
Keywords
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
W. Wolfgang Fleischhacker, Ireneus P.M. Keet, René S. Kahn, EUFEST Steering Committee EUFEST Steering Committee,